Who is the CEO of AVROBIO, Inc.?

Mr. Erik John Ostrowski M.B.A. is a business executive who currently serves as the CEO of AVROBIO, Inc..

What is the Revenue Growth of AVROBIO, Inc.?

Revenue growth data for AVROBIO, Inc. is currently unavailable.

What is AVROBIO, Inc. operating Margin?

AVROBIO, Inc. operating margin is 1867.57% which shows how much profit AVRO earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does AVROBIO, Inc. operate?

AVROBIO, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is AVROBIO, Inc. revenue growth?

Revenue growth data for AVROBIO, Inc. is currently unavailable.

AVROBIO, Inc.

AVRO•NASDAQ

HealthcareBiotechnology

$1.40

$-0.02(-1.41%)

AVROBIO, Inc. (AVRO) Stock Overview

Explore AVROBIO, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for AVROStats details for AVRO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for AVROAnalyst Recommendations details for AVRO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO

Mr. Erik John Ostrowski M.B.A.

Employees

Headquarters

Building 300, Cambridge, MA

Founded

2018